---
schema_version: "secwatch.filing_event.v1"
accession: "0001798749-24-000039"
form_type: "8-K/A"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2024-07-01T23:59:59+00:00"
generated_at: "2026-06-01T00:06:04.559990+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aerovate Therapeutics to reduce nearly all workforce after ending AV-101 trial

## Summary
- On June 25, 2024, Aerovate began workforce reduction after ending AV-101 clinical program.
- First wave: 39 employees (78% of workforce) terminated; nearly all remaining staff to be let go.
- Estimated $5.6 million in severance costs, mostly one-time, to be incurred in Q3 and Q4 2024.
- Severance contingent on separation agreements with general release of claims.

## SEC filing metadata
- accession: 0001798749-24-000039
- form_type: 8-K/A
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2024-07-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000179874924000039/0001798749-24-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000179874924000039/tmb-20240625x8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001798749-24-000039
- JSON: https://secwatch.observer/filing/0001798749-24-000039.json
- Plain text: https://secwatch.observer/filing/0001798749-24-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.